Tapentadol versus oxycodone analgesia and side effects after laparoscopic hysterectomy: A randomised controlled trial.

Eur J Anaesthesiol

From the Division of Emergencies and Critical Care, Department of Anaesthesiology, Oslo University Hospital (MC, JR, HL), Faculty of Medicine, Institute of Clinical Medicine, University of Oslo (MC, JR, TD, ML, HL), Division of Emergencies and Critical Care, Department of Research and Development (TD) and Division of Gynaecology and Obstetrics, Oslo University Hospital, Oslo, Norway (ML).

Published: September 2021

Background: Tapentadol is an opioid, which acts as a μ-opioid receptor agonist and inhibits noradrenaline reuptake in the central nervous system. This dual mechanism of action results in synergistic analgesic effects and potentially less side effects. This has been shown in treatment of chronic pain but postoperative studies are sparse.

Objectives: The main aim was to compare the analgesic effect of tapentadol with oxycodone after laparoscopic hysterectomy. Opioid side effects were recorded as secondary outcomes.

Design: Randomised, blinded trial.

Setting: Single-centre, Oslo University Hospital, Norway, December 2017 to February 2019.

Patients: Eighty-six opioid-naïve American Society of Anesthesiologists physical status 1 to 3 women undergoing laparoscopic hysterectomy for nonmalignant conditions.

Intervention: The patients received either oral tapentadol (group T) or oxycodone (group O) as part of multimodal pain treatment. Extended-release study medicine was administered 1 h preoperatively and after 12 h. Immediate-release study medicine was used as rescue analgesia.

Main Outcome Measures: Pain scores, opioid consumption and opioid-induced side effects were evaluated during the first 24 h after surgery.

Results: The groups scored similarly for pain at rest using a numerical rating scale (NRS) 1 h postoperatively (group T 4.4, 95% CI, 3.8 to 5.0, group O 4.6, 95% CI, 3.8 to 5.3). No statistically significant differences were found between the groups for NRS at rest or while coughing during the 24-h follow-up period (P = 0.857 and P = 0.973). Mean dose of oral rescue medicine was similar for the groups (P = 0.914). Group T had significantly lower odds for nausea at 2 and 3 h postoperatively (P = 0.040, P = 0.020) and less need for antiemetics than group O. No differences were found for respiratory depression, vomiting, dizziness, pruritus, headache or sedation.

Conclusion: We found tapentadol to be similar in analgesic efficacy to oxycodone during the first 24 h after hysterectomy, but with significantly less nausea.

Trial Registration: ClinicalTrials.gov, NCT03314792.

Download full-text PDF

Source
http://dx.doi.org/10.1097/EJA.0000000000001425DOI Listing

Publication Analysis

Top Keywords

side effects
16
laparoscopic hysterectomy
12
study medicine
8
group 95%
8
group
6
tapentadol
5
effects
5
tapentadol versus
4
oxycodone
4
versus oxycodone
4

Similar Publications

Background: Polycystic Ovarian Syndrome (PCOS) is an endocrine disorder associated with increased risk of kidney and liver damage. Current treatments have shown contradictory outcomes, and their long-term use causes unwanted side effects. could serve as a complementary medicine to current PCOS treatments.

View Article and Find Full Text PDF

Effects of the 2022 Oder River environmental disaster on fish gill structure.

Dis Aquat Organ

January 2025

Department of Hydrobiology, Ichthyology and Biotechnology of Reproduction, West Pomeranian University of Technology in Szczecin, Kazimierza Królewicza 4, 71-550 Szczecin, Poland.

The 2022 Oder River disaster was one of the most significant harmful events in recent European river history, with an estimated 60% reduction in fish biomass in the lower section of the river. While the prevailing hypothesis attributes associated fish kills to toxins from golden algae Prymnesium parvum, our histopathological study on the gills of 2 common cyprinid fish species, namely vimba bream Vimba vimba (L.) and roach Rutilus rutilus (L.

View Article and Find Full Text PDF

Reductive Adjuvant Nanosystem for Alleviated Atopic Dermatitis Syndromes.

ACS Nano

January 2025

College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.

Atopic dermatitis (AD) is a recurrent and chronic inflammatory skin condition characterized by a high lifetime prevalence and significant impairment of patients' quality of life, primarily due to intense itching and discomfort. However, current pharmacological interventions provide only moderate efficacy and are frequently accompanied by adverse side effects. The immune-pathogenesis of AD involves dysregulation of the Th2 immune response and exacerbation of inflammation related to excessive reactive oxygen species (ROS).

View Article and Find Full Text PDF

Minimising inhaled corticosteroids for COPD.

Afr J Prim Health Care Fam Med

December 2024

Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.

This Therapeutic Letter considers the evidence for inhaled corticosteroids (ICS) as a treatment for Chronic Obstructive Pulmonary Disease (COPD). Drug therapy aims to alleviate symptoms, enhance functional capacity and prevent exacerbations, but has not consistently shown to reduce mortality or improve quality of life based on randomised trials.Inhaled corticosteroids have shown limited benefits for COPD symptoms and exacerbations but increased risks of serious harms.

View Article and Find Full Text PDF

Minimising harms of tight glycaemic control in older patients with type 2 diabetes.

Afr J Prim Health Care Fam Med

December 2024

Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.

In older adults with type 2 diabetes (T2DM), tight glycaemic control (HbA1c 7%) can result in more harm than benefit, especially when using insulin or sulfonylureas. Older adults are at higher risk for adverse drug events, especially hypoglycaemia, which may cause falls, confusion and hospitalisations. This Therapeutic Letter evaluates the risks of tight glycaemic control in older adults with T2DM, focusing on deprescribing diabetes medications in those over 65, especially those with multimorbidity and polypharmacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!